Keros Therapeutics Reports First Quarter 2022 Financial Results
05. Mai 2022 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery,...
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results
09. März 2022 16:01 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery,...
Keros Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
11. Februar 2022 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (NASDAQ: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics Appoints Christopher Rovaldi as Chief Operating Officer
31. Januar 2022 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Corrected: Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition
13. Dezember 2021 16:05 ET
|
Keros Therapeutics, Inc.
Lexington, Mass. – December 13, 2021 – Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS) is re-issuing this press release solely to correct inadvertent typographical errors under the heading "A Phase...
Keros Therapeutics Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to KER-050 in China
13. Dezember 2021 08:00 ET
|
Keros Therapeutics, Inc.
Keros Therapeutics to receive potential milestone payments up to $170.5 million, $20 million upfront, and tiered royalty payments in the low double digit to high teens on net product sales LEXINGTON,...
Keros Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
22. November 2021 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 at the American Heart Association 2021 Scientific Sessions
15. November 2021 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics to Present at the Jefferies Virtual London Healthcare Conference
11. November 2021 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics to Present Results from a Preclinical Study of RKER-012 at the American Heart Association 2021 Scientific Sessions
08. November 2021 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...